Tus-Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 3/6
Tus-Pharmaceutical Group has a total shareholder equity of CN¥700.3M and total debt of CN¥103.4M, which brings its debt-to-equity ratio to 14.8%. Its total assets and total liabilities are CN¥1.1B and CN¥407.2M respectively.
Key information
14.8%
Debt to equity ratio
CN¥103.43m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥190.36m |
| Equity | CN¥700.32m |
| Total liabilities | CN¥407.17m |
| Total assets | CN¥1.11b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 000590's short term assets (CN¥484.5M) exceed its short term liabilities (CN¥217.9M).
Long Term Liabilities: 000590's short term assets (CN¥484.5M) exceed its long term liabilities (CN¥189.3M).
Debt to Equity History and Analysis
Debt Level: 000590 has more cash than its total debt.
Reducing Debt: 000590's debt to equity ratio has increased from 5% to 14.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if 000590 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 000590 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.